JP6574477B2 - ルカパリブの高投与力価錠剤 - Google Patents

ルカパリブの高投与力価錠剤 Download PDF

Info

Publication number: JP6574477B2
Authority: JP; Japan
Prior art keywords: tablet; contained; range; cansylate; formulation
Prior art date: 2014-08-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

JP2017510539A

Other languages

English (en)

Japanese (ja)

Other versions

JP2017525712A (ja

JP2017525712A5 (2

Inventor

エッター，ジェフリー

Original Assignee

クロヴィス・オンコロジー，インコーポレーテッド

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-08-22

Filing date

2015-08-17

Publication date

2019-09-11

2015-08-17 Application filed by クロヴィス・オンコロジー，インコーポレーテッド filed Critical クロヴィス・オンコロジー，インコーポレーテッド

2017-09-07 Publication of JP2017525712A publication Critical patent/JP2017525712A/ja

2018-09-27 Publication of JP2017525712A5 publication Critical patent/JP2017525712A5/ja

2019-09-11 Application granted granted Critical

2019-09-11 Publication of JP6574477B2 publication Critical patent/JP6574477B2/ja

Status Active legal-status Critical Current

2035-08-17 Anticipated expiration legal-status Critical

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Inorganic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

JP2017510539A 2014-08-22 2015-08-17 ルカパリブの高投与力価錠剤 Active JP6574477B2 (ja)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US201462040849P	2014-08-22	2014-08-22
US62/040,849		2014-08-22
US201562101739P	2015-01-09	2015-01-09
US62/101,739		2015-01-09
PCT/US2015/045522 WO2016028689A1 (en)	2014-08-22	2015-08-17	High dosage strength tablets of rucaparib

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2019149084A Division JP6797980B2 (ja)	2014-08-22	2019-08-15	ルカパリブの高投与力価錠剤

Publications (3)

Publication Number	Publication Date
JP2017525712A JP2017525712A (ja)	2017-09-07
JP2017525712A5 JP2017525712A5 (2)	2018-09-27
JP6574477B2 true JP6574477B2 (ja)	2019-09-11

Family

ID=55347324

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
JP2017510539A Active JP6574477B2 (ja)	2014-08-22	2015-08-17	ルカパリブの高投与力価錠剤
JP2019149084A Active JP6797980B2 (ja)	2014-08-22	2019-08-15	ルカパリブの高投与力価錠剤
JP2020191356A Active JP7127101B2 (ja)	2014-08-22	2020-11-18	ルカパリブの高投与力価錠剤

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
JP2019149084A Active JP6797980B2 (ja)	2014-08-22	2019-08-15	ルカパリブの高投与力価錠剤
JP2020191356A Active JP7127101B2 (ja)	2014-08-22	2020-11-18	ルカパリブの高投与力価錠剤

Country Status (23)

Country	Link
US (3)	US9987285B2 (2)
EP (1)	EP3182975B1 (2)
JP (3)	JP6574477B2 (2)
KR (2)	KR102803917B1 (2)
CN (2)	CN106794185A (2)
AU (2)	AU2015305696B2 (2)
BR (1)	BR112017000865A2 (2)
CA (1)	CA2955495C (2)
DK (1)	DK3182975T3 (2)
ES (1)	ES3048688T3 (2)
FI (1)	FI3182975T3 (2)
HR (1)	HRP20251484T1 (2)
IL (1)	IL249946B (2)
LT (1)	LT3182975T (2)
MX (1)	MX367260B (2)
NZ (1)	NZ728392A (2)
PL (1)	PL3182975T3 (2)
PT (1)	PT3182975T (2)
RS (1)	RS67356B1 (2)
RU (1)	RU2705156C2 (2)
SG (1)	SG11201700265VA (2)
SI (1)	SI3182975T1 (2)
WO (1)	WO2016028689A1 (2)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2021038242A (ja) *	2014-08-22	2021-03-11	クロヴィス・オンコロジー，インコーポレーテッド	ルカパリブの高投与力価錠剤

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US12168004B2 (en)	2014-02-05	2024-12-17	Merck Sharp & Dohme Llc	Treatment of migraine
RU2019123406A (ru)	2014-02-05	2019-10-03	Мерк Шарп И Доум Корп.	Технология приготовления таблеток для cgrp-активных соединений
CN106008530B (zh) *	2016-07-24	2018-06-26	石家庄久正生物科技有限公司	一种抗卵巢癌药物Rucaparib关键中间体的制备方法
CN108201534A (zh) *	2016-12-16	2018-06-26	苏州苏融生物医药有限公司	一种瑞卡帕布口服缓控释药物组合物及其用途
WO2018140377A1 (en)	2017-01-24	2018-08-02	Assia Chemical Industries Ltd.	Solid state forms of rucaparib and of rucaparib salts
CN110944638A (zh)	2017-03-27	2020-03-31	特沙诺有限公司	尼拉帕尼组合物
TWI843707B (zh) *	2017-09-26	2024-06-01	美商提薩羅有限公司	尼拉帕尼（ｎｉｒａｐａｒｉｂ）調配物
WO2019130229A1 (en)	2017-12-28	2019-07-04	Mylan Laboratories Ltd	Methods and intermediates for preparing rucaparib
KR20200121800A (ko)	2018-01-05	2020-10-26	싸이브렉사 1, 인크.	산성 또는 저산소성 질환에 걸린 조직에 관련된 질환의 치료를 위한 화합물, 조성물 및 방법
US12383545B1 (en)	2018-06-08	2025-08-12	Allergan Pharmaceuticals International Limited	Treatment of migraine
CN109111454A (zh) *	2018-08-01	2019-01-01	宁波金未生物科技有限公司	一种瑞卡帕布s-樟脑磺酸盐
CN108853030B (zh) *	2018-09-26	2021-10-01	上海朝晖药业有限公司	一种治疗恶性肿瘤的药物制剂及其制备方法
CN111542527A (zh)	2018-12-06	2020-08-14	上海诚妙医药科技有限公司	芦卡帕利樟脑磺酸盐的新晶型和制备方法及其用途
US11555019B2 (en)	2019-07-10	2023-01-17	Cybrexa 3, Inc.	Peptide conjugates of microtubule-targeting agents as therapeutics
MX2022000449A (es)	2019-07-10	2022-04-25	Cybrexa 2 Inc	Conjugados peptídicos de citotoxinas como terapéuticos.
US20230234938A1 (en)	2020-04-28	2023-07-27	Rhizen Pharmaceuticals Ag	Novel compounds useful as poly(adp-ribose) polymerase (parp) inhibitors
EP4182318B1 (en)	2020-07-14	2025-08-27	Assia Chemical Industries Ltd.	Solid state forms of rucaparib salts
CN116390712A (zh)	2020-07-29	2023-07-04	阿勒根制药国际有限公司	治疗偏头痛
WO2022090938A1 (en)	2020-10-31	2022-05-05	Rhizen Pharmaceuticals Ag	Phthalazinone derivatives useful as parp inhibitors
CA3206184A1 (en)	2020-12-22	2022-06-30	Allergan Pharmaceuticals International Limited	Treatment of migraine
CA3214298A1 (en)	2021-04-08	2022-10-13	Swaroop Kumar Venkata Satya VAKKALANKA	Inhibitors of poly(adp-ribose) polymerase
EP4408418A1 (en)	2021-09-27	2024-08-07	Allergan Pharmaceuticals International Limited	Combination comprising atogepant for treating migraine
JP2024543323A (ja) *	2021-11-10	2024-11-21	クリチテック，インコーポレイテッド	ルカパリブ粒子およびその使用
EP4463232A1 (en)	2022-01-11	2024-11-20	Assia Chemical Industries Ltd.	Solid state forms of rucaparib tosylate

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6495541B1 (en)	1999-01-11	2002-12-17	Agouron Pharmaceuticals, Inc.	Tricyclic inhibitors of poly(ADP-ribose) polymerases
CA2520997A1 (en)	2003-03-31	2004-10-14	Stacie Sara Canan-Koch	Salts of tricyclic inhibitors of poly(adp-ribose) polymerases
US7531530B2 (en)	2003-07-25	2009-05-12	Cancer Research Technology Limited	Therapeutic compounds
MX2007003314A (es)	2004-09-22	2007-08-06	Pfizer	Combinaciones terapeuticas que comprenden inhibidor de poli(adp-ribosa)polimerasas.
ATE551345T1 (de)	2004-09-22	2012-04-15	Pfizer	Polymorphe formen des phosphatsalzes von 8-fluor- 2-ä4-ä(methylamino)methylüphenylü-1,3,4,5- tetrahydro-6h-azepinoä5,4,3-cdüindol-6-on
PT1794163E (pt)	2004-09-22	2010-03-01	Pfizer	Método para a preparação de inibidores de poli(adpribose)- polimerases
CA2720744A1 (en) *	2008-04-09	2009-10-15	Lek Pharmaceuticals D.D.	Granulation of active pharmaceutical ingredients
EP4166558A1 (en)	2010-02-12	2023-04-19	Pfizer Inc.	Salts and polymorphs of 8-fluoro-2-{4- [(methylamino)methyl]phenyl}-1 ,3,4,5-tetrahydro-6h-azepino[5,4,3- cd]indol-6-one
CN108478577A (zh) *	2012-04-05	2018-09-04	沃泰克斯药物股份有限公司	可用作atr激酶抑制剂的化合物及其组合疗法
AU2015305696B2 (en)	2014-08-22	2019-08-29	Pharma& Schweiz Gmbh	High dosage strength tablets of rucaparib

2015
- 2015-08-17 AU AU2015305696A patent/AU2015305696B2/en active Active
- 2015-08-17 CN CN201580042815.9A patent/CN106794185A/zh active Pending
- 2015-08-17 NZ NZ728392A patent/NZ728392A/en unknown
- 2015-08-17 US US14/828,065 patent/US9987285B2/en active Active
- 2015-08-17 WO PCT/US2015/045522 patent/WO2016028689A1/en not_active Ceased
- 2015-08-17 ES ES15833096T patent/ES3048688T3/es active Active
- 2015-08-17 MX MX2017001540A patent/MX367260B/es active IP Right Grant
- 2015-08-17 JP JP2017510539A patent/JP6574477B2/ja active Active
- 2015-08-17 KR KR1020237020594A patent/KR102803917B1/ko active Active
- 2015-08-17 SI SI201532081T patent/SI3182975T1/sl unknown
- 2015-08-17 SG SG11201700265VA patent/SG11201700265VA/en unknown
- 2015-08-17 DK DK15833096.9T patent/DK3182975T3/da active
- 2015-08-17 HR HRP20251484TT patent/HRP20251484T1/hr unknown
- 2015-08-17 CA CA2955495A patent/CA2955495C/en active Active
- 2015-08-17 FI FIEP15833096.9T patent/FI3182975T3/fi active
- 2015-08-17 LT LTEPPCT/US2015/045522T patent/LT3182975T/lt unknown
- 2015-08-17 PT PT158330969T patent/PT3182975T/pt unknown
- 2015-08-17 BR BR112017000865A patent/BR112017000865A2/pt not_active Application Discontinuation
- 2015-08-17 PL PL15833096.9T patent/PL3182975T3/pl unknown
- 2015-08-17 RU RU2017109139A patent/RU2705156C2/ru active
- 2015-08-17 EP EP15833096.9A patent/EP3182975B1/en active Active
- 2015-08-17 KR KR1020177007284A patent/KR20170043597A/ko not_active Ceased
- 2015-08-17 CN CN202110458329.2A patent/CN113209033A/zh active Pending
- 2015-08-17 RS RS20251082A patent/RS67356B1/sr unknown
2017
- 2017-01-05 IL IL249946A patent/IL249946B/en active IP Right Grant
2018
- 2018-03-14 US US15/920,643 patent/US10130636B2/en active Active
- 2018-10-08 US US16/154,038 patent/US20190099430A1/en not_active Abandoned
2019
- 2019-08-15 JP JP2019149084A patent/JP6797980B2/ja active Active
- 2019-11-29 AU AU2019272064A patent/AU2019272064B2/en active Active
2020
- 2020-11-18 JP JP2020191356A patent/JP7127101B2/ja active Active

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2021038242A (ja) *	2014-08-22	2021-03-11	クロヴィス・オンコロジー，インコーポレーテッド	ルカパリブの高投与力価錠剤

Also Published As

Publication number	Publication date
DK3182975T3 (da)	2025-10-20
IL249946B (en)	2020-05-31
SI3182975T1 (sl)	2025-12-31
RS67356B1 (sr)	2025-11-28
AU2015305696A1 (en)	2017-02-02
FI3182975T3 (fi)	2025-11-13
JP2017525712A (ja)	2017-09-07
JP7127101B2 (ja)	2022-08-29
US9987285B2 (en)	2018-06-05
US10130636B2 (en)	2018-11-20
AU2019272064B2 (en)	2021-11-18
CA2955495C (en)	2023-09-19
US20160051561A1 (en)	2016-02-25
AU2015305696B2 (en)	2019-08-29
KR20170043597A (ko)	2017-04-21
WO2016028689A1 (en)	2016-02-25
NZ728392A (en)	2023-06-30
MX367260B (es)	2019-08-12
RU2017109139A3 (2)	2019-03-06
CN113209033A (zh)	2021-08-06
CN106794185A (zh)	2017-05-31
US20180200260A1 (en)	2018-07-19
KR102803917B1 (ko)	2025-05-07
BR112017000865A2 (pt)	2017-12-05
EP3182975A4 (en)	2018-04-18
PT3182975T (pt)	2025-10-28
LT3182975T (lt)	2025-11-25
RU2017109139A (ru)	2018-09-24
HRP20251484T1 (hr)	2026-01-02
PL3182975T3 (pl)	2026-02-23
ES3048688T3 (en)	2025-12-11
EP3182975A1 (en)	2017-06-28
AU2019272064A1 (en)	2019-12-19
JP2020002149A (ja)	2020-01-09
JP2021038242A (ja)	2021-03-11
EP3182975B1 (en)	2025-10-01
SG11201700265VA (en)	2017-02-27
US20190099430A1 (en)	2019-04-04
KR20230097211A (ko)	2023-06-30
CA2955495A1 (en)	2016-02-25
IL249946A0 (en)	2017-03-30
MX2017001540A (es)	2017-05-11
JP6797980B2 (ja)	2020-12-09
RU2705156C2 (ru)	2019-11-05

Legal Events

Date	Code	Title	Description
2018-08-16	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180816
2018-08-16	A621	Written request for application examination	Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180816
2018-08-16	A871	Explanation of circumstances concerning accelerated examination	Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20180816
2018-08-29	A975	Report on accelerated examination	Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20180829
2018-09-19	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180919
2018-12-19	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20181219
2019-03-19	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190319
2019-04-02	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190402
2019-06-27	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190627
2019-06-28	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190628
2019-07-05	TRDD	Decision of grant or rejection written
2019-07-18	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190718
2019-08-22	A61	First payment of annual fees (during grant procedure)	Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190816
2019-08-23	R150	Certificate of patent or registration of utility model	Ref document number: 6574477 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150
2022-07-29	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2023-07-31	S111	Request for change of ownership or part of ownership	Free format text: JAPANESE INTERMEDIATE CODE: R313113
2023-08-08	R350	Written notification of registration of transfer	Free format text: JAPANESE INTERMEDIATE CODE: R350
2023-08-10	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2024-08-21	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2025-08-20	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250

Publication	Publication Date	Title
JP6574477B2 (ja)	2019-09-11	ルカパリブの高投与力価錠剤
EP3606511B1 (en)	2022-04-20	Pharmaceutical composition comprising lenvatinib mesylate
JP2016536285A (ja)	2016-11-24	アムロジピン及びバルサルタンを含む安定な医薬組成物
JP7455189B2 (ja)	2024-03-25	プレトマニド組成物
TWI418370B (zh)	2013-12-11	溶出安定性製劑
EP3860606B1 (en)	2023-11-08	Pharmaceutical composition comprising lenvatinib esylate or tosylate
US20070172521A1 (en)	2007-07-26	Levetiracetam formulations and methods for their manufacture
WO2023111187A1 (en)	2023-06-22	Pharmaceutical compositions comprising eltrombopag
JP2017520619A (ja)	2017-07-27	セリチニブ製剤
WO2016139681A2 (en)	2016-09-09	Pharmaceutical composition of tizanidine and process for preparing the same
EA051960B1 (ru)	2025-12-24	Фармацевтическая композиция бемпедоевой кислоты
WO2025018960A1 (en)	2025-01-23	A film coated tablet of brivaracetam
HK1232807A1 (en)	2018-01-19	High dosage strength tablets of rucaparib
KR20240055103A (ko)	2024-04-26	벰페도산의 약학 조성물
HK1232807B (en)	2025-12-12	High dosage strength tablets of rucaparib
CZ20002303A3 (cs)	2000-11-15	Perorálně podávatelné pevné ribavirinové dávkové formy a způsob jejich přípravy

JP6574477B2 - ルカパリブの高投与力価錠剤 - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (5)

Related Child Applications (1)

Publications (3)

Family

ID=55347324

Family Applications (3)

Family Applications After (2)

Country Status (23)

Cited By (1)

Families Citing this family (24)

Family Cites Families (10)

Cited By (1)

Also Published As

Similar Documents

Legal Events